nach oben

Erschienen in:

01.08.2012 | Original Paper

Growth Hormone-Releasing Hormone Receptor Splice Variant 1 is Frequently Expressed in Oral Squamous Cell Carcinomas

verfasst von: Nikolina Dioufa, Elena Farmaki, Andrew V. Schally, Hippokratis Kiaris, Dimitris Vlahodimitropoulos, Athanasios G. Papavassiliou, Christos Kittas, Norman L. Block, Ioulia Chatzistamou

Erschienen in: Discover Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The expression of growth hormone-releasing hormone (GHRH) splice variant 1 (SV1) receptor in neoplastic lesions of the oral cavity was assessed. The sensitivity of HaCaT keratinocytes to GHRH analogs was also evaluated. Thirty-three benign precancerous oral lesions and 27 squamous cell carcinomas of the oral cavity were evaluated by immunohistochemistry for SV1 expression. SV1 expression in HaCaT keratinocytes was assessed by western blot. HaCaT proliferation was evaluated by cell counting. Anti-SV1 immunoreactivity was detected in only 9 % (three of 33) precancerous lesions (one hyperplasia and two dysplasias), while 44 % (12 of 27) carcinomas were positive for SV1 (p < 0.002). GHRH(1–29)NH₂ and GHRH agonist JI-38 stimulated HaCaT proliferation in vitro, and this effect was blocked by GHRH antagonists. These results indicate that SV1 expression may be associated with the transition of precancerous lesions to carcinomas of the oral epithelium. GHRH antagonists may be useful for the management of the disease.

Warnakulasuriya S (2010) Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncol 46(6):407–410PubMedCrossRef

Lambert R, Sauvaget C, de Camargo CM, Sankaranarayanan R (2011) Epidemiology of cancer from the oral cavity and oropharynx. Eur J Gastroenterol Hepatol 23:633–641PubMedCrossRef

Znaor A, Brennan P, Gajalakshmi V, Mathew A, Shanta V, Varghese C, Boffetta P (2003) Independent and combined effects of tobacco smoking, chewing and alcohol drinking on the risk of oral, pharyngeal and esophageal cancers in Indian men. Int J Cancer 105(5):681–686PubMedCrossRef

Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G, Vinoda J, Sankaranarayanan R (2008) Role of tobacco smoking, chewing and alcohol drinking in the risk of oral cancer in Trivandrum, India: a nested case–control design using incident cancer cases. Oral Oncol 44(5):446–454PubMedCrossRef

Izumo T (2011) Oral premalignant lesions: from the pathological viewpoint. Int J Clin Oncol 16(1):15–26PubMedCrossRef

Ogmundsdóttir HM, Björnsson J, Holbrook WP (2009) Role of TP53 in the progression of pre-malignant and malignant oral mucosal lesions. A follow-up study of 144 patients. J Oral Pathol Med 38(7):565–571PubMedCrossRef

Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG (2010) Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol 2:13PubMedCrossRef

Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L (2010) Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) 3(7):800–809CrossRef

Bernardes VF, Gleber-Netto FO, Sousa SF, Silva TA, Aguiar MC (2010) Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study. J Exp Clin Cancer Res 29:40PubMedCrossRef

10.

Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Forteza J, Fraga M (2010) EGFR and Ki-67 expression in oral squamous cell carcinoma using tissue microarray technology. J Oral Pathol Med 39(7):571–578PubMed

11.

Tilakaratne WM, Kobayashi T, Ida-Yonemochi H, Swelam W, Yamazaki M, Mikami T, Alvarado CG, Shahidul AM, Maruyama S, Cheng J, Saku T (2009) Matrix metalloproteinase 7 and perlecan in oral epithelial dysplasia and carcinoma in situ: an aid for histopathologic recognition of their cell proliferation centers. J Oral Pathol Med 38(4):348–355PubMedCrossRef

12.

Thomas GT, Lewis MP, Speight PM (1999) Matrix metalloproteinases and oral cancer. Oral Oncol 35(3):227–233PubMedCrossRef

13.

Kuo MY, Chang HH, Hahn LJ, Wang JT, Chiang CP (1995) Elevated ras p21 expression in oral premalignant lesions and squamous cell carcinoma in Taiwan. J Oral Pathol Med 24(6):255–260PubMedCrossRef

14.

Kiaris H, Spandidos DA, Jones AS, Vaughan ED, Field JK (1995) Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer 72(1):123–128PubMedCrossRef

15.

Kiaris H, Spandidos D, Jones A, Field J (1994) Loss of heterozygosity and microsatellite instability of the H-ras gene in cancer of the head and neck. Int J Oncol 5(3):579–582PubMed

16.

Paterson IC, Eveson JW, Prime SS (1996) Molecular changes in oral cancer may reflect aetiology and ethnic origin. J Cancer B Oral Oncol 32B(3):150–153CrossRef

17.

Syrjänen S, Lodi G, von Bültzingslöwen I, Aliko A, Arduino P, Campisi G, Challacombe S, Ficarra G, Flaitz C, Zhou HM, Maeda H, Miller C, Jontell M (2011) Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 17(Suppl 1):58–72PubMedCrossRef

18.

Angiero F, Gatta LB, Seramondi R, Berenzi A, Benetti A, Magistro S, Ordesi P, Grigolato P, Dessy E (2010) Frequency and role of HPV in the progression of epithelial dysplasia to oral cancer. Anticancer Res 30(9):3435–3440PubMed

19.

Chatzistamou I, Dioufa N, Trimis G, Sklavounou A, Kittas C, Kiaris H, Papavassiliou AG (2010) p21/waf1 and smooth-muscle actin α expression in stromal fibroblasts of oral cancers. Anal Cell Pathol (Amst) 33(1):19–26

20.

Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, Upile T, Kalavrezos N, Violette SM, Weinreb PH, Chester KA, Chana JS, Marshall JF, Hart IR, Hackshaw AK, Piper K, Thomas GJ (2011) Stromal features are predictive of disease mortality in oral cancer patients. J Pathol 223(4):470–481PubMedCrossRef

21.

Meng W, Xia Q, Wu L, Chen S, He X, Zhang L, Gao Q, Zhou H (2011) Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts. BMC Cancer 11:88PubMedCrossRef

22.

Hiraishi Y, Wada T, Nakatani K, Tojyo I, Matsumoto T, Kiga N, Negoro K, Fujita S (2008) EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines. Pathol Oncol Res 14(1):39–43PubMedCrossRef

23.

Holsinger FC, Doan DD, Jasser SA, Swan EA, Greenberg JS, Schiff BA, Bekele BN, Younes MN, Bucana CD, Fidler IJ, Myers JN (2003) Epidermal growth factor receptor blockade potentiates apoptosis mediated by paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 9(8):3183–3189PubMed

24.

Ludwig B, Ziegler CG, Schally AV, Richter C, Steffen A, Jabs N, Funk RH, Brendel MD, Block NL, Ehrhart-Bornstein M, Bornstein SR (2010) Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc Natl Acad Sci U S A 107(28):12623–12628PubMedCrossRef

25.

Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM, Treuer AV, Lamirault G, Dulce R, Hurtado M, Song Y, Block NL, Rick F, Klukovits A, Hu Q, Varga JL, Schally AV, Hare JM (2010) Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci U S A 107(6):2604–2609PubMedCrossRef

26.

Granata R, Trovato L, Gallo MP, Destefanis S, Settanni F, Scarlatti F, Brero A, Ramella R, Volante M, Isgaard J, Levi R, Papotti M, Alloatti G, Ghigo E (2009) Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia–reperfusion injury in rat heart. Cardiovasc Res 83(2):303–312PubMedCrossRef

27.

Kiaris H, Chatzistamou I, Papavassiliou AG, Schally AV (2011) Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol Metab 22:311–317PubMedCrossRef

28.

Schally AV, Varga JL, Engel JB (2008) Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4(1):33–43PubMedCrossRef

29.

Kiaris H, Schally AV, Kalofoutis A (2005) Extrapituitary effects of the growth hormone-releasing hormone. Vitam Horm 70:1–24PubMedCrossRef

30.

Barabutis N, Schally AV (2010) Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle 9(20):4110–4116PubMedCrossRef

31.

Rekasi Z, Czompoly T, Schally AV, Halmos G (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A 97:10561–10566PubMedCrossRef

32.

Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, Szepeshazi K, Köster F, Kovitz K, Groot K, Zarandi M, Kanashiro CA (2005) The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci U S A 102(48):17424–17429PubMedCrossRef

33.

Theophanous E, Petraki C, Scorilas A, Komborozos V, Veloudis G, Varga JL, Zarandi M, Schally AV, Koutsilieris M (2009) The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. Mol Med 15(7–8):242–247PubMed

34.

Köster F, Engel JB, Schally AV, Hönig A, Schröer A, Seitz S, Hohla F, Ortmann O, Diedrich K, Buchholz S (2009) Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Res Treat 116(2):273–279PubMedCrossRef

35.

Schulz S, Röcken C, Schulz S (2006) Immunocytochemical localisation of plasma membrane GHRH receptors in human tumours using a novel anti-peptide antibody. Eur J Cancer 42(14):2390–2396PubMedCrossRef

36.

Chatzistamou I, Volakaki AA, Schally AV, Kiaris H, Kittas C (2008) Expression of growth hormone-releasing hormone receptor splice variant 1 in primary human melanomas. Regul Pept 147(1–3):33–36PubMedCrossRef

37.

Kiaris H, Schally AV, Busto R, Halmos G, Artavanis-Tsakonas S, Varga JL (2002) Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proc Natl Acad Sci U S A 99(1):196–200PubMedCrossRef

38.

Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga JL, Koutselini H, Kalofoutis A (2003) Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proc Natl Acad Sci U S A 100(16):9512–9517PubMedCrossRef

39.

Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H (2007) Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proc Natl Acad Sci U S A 104:5575–5579PubMedCrossRef

40.

Izdebski J, Pinski J, Horvath JE, Halmos G, Groot K, Schally AV (1995) Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone. Proc Natl Acad Sci U S A 92(11):4872–4876PubMedCrossRef

41.

Letsch M, Schally AV, Busto R, Bajo AM, Varga JL (2003) Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci U S A 100:1250–1255PubMedCrossRef

42.

Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL, Halmos G (2007) Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci U S A 104(6):1943–1946PubMedCrossRef

43.

Dioufa N, Schally AV, Chatzistamou I, Moustou E, Block NL, Owens GK, Papavassiliou AG, Kiaris H (2010) Acceleration of wound healing by growth hormone-releasing hormone and its agonists. Proc Natl Acad Sci U S A 107(43):18611–18615PubMedCrossRef

44.

Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761–771PubMedCrossRef

Titel: Growth Hormone-Releasing Hormone Receptor Splice Variant 1 is Frequently Expressed in Oral Squamous Cell Carcinomas
verfasst von: Nikolina Dioufa
Elena Farmaki
Andrew V. Schally
Hippokratis Kiaris
Dimitris Vlahodimitropoulos
Athanasios G. Papavassiliou
Christos Kittas
Norman L. Block
Ioulia Chatzistamou
Publikationsdatum: 01.08.2012
Verlag: Springer-Verlag
Erschienen in: Discover Oncology / Ausgabe 4/2012
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-012-0108-8

Springer Medizin

Growth Hormone-Releasing Hormone Receptor Splice Variant 1 is Frequently Expressed in Oral Squamous Cell Carcinomas

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Systematic Review and Meta-analysis of Insulin Therapy and Risk of Cancer

Apigenin Induces Apoptosis and Blocks Growth of Medroxyprogesterone Acetate-Dependent BT-474 Xenograft Tumors

Extended RET Gene Analysis in Patients with Apparently Sporadic Medullary Thyroid Cancer: Clinical Benefits and Cost

Somatic Mutation Analysis of the SDHB, SDHC, SDHD, and RET Genes in the Clinical Assessment of Sporadic and Hereditary Pheochromocytoma

Translational Highlights

Association of Double-Positive FOXA1 and FOXP1 Immunoreactivities with Favorable Prognosis of Tamoxifen-Treated Breast Cancer Patients

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie